Risk of ipsilateral breast event after surgical excision increases over time
the ONA take:
Women with ductal carcinoma in situ (DCIS) who undergo surgical resection without radiation have an increased risk of developing recurrence of DCIS or invasive disease, and that risk increases over time.
A prospective clinical trial sought to determine the 12-year risk of an ipsilateral breast event (IBE) in women with DCIS of the breast treated with lumpectomy without radiation. The results were presented in part at the San Antonio Breast Cancer Symposium.
Study participants were enrolled into two cohorts, not randomly assigned. Cohort 1 was 561 patients with low- or intermediate grade DCIS, tumor size 2.5 cm or smaller. Cohort 2 was 104 patients with high-grade DCIS, tumor size 1 cm or smaller.
Patients underwent excision of the DCIS tumor with a minimum negative margin width of at least 3 mm, and 30% of the patients received tamoxifen (not randomly assigned). An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast. Patients were followed for a median of 12.3 years. There were 99 IBEs, of which 51 were invasive.
Results show that 12-year rates of developing an IBE was 14.4% for cohort 1 and 24.6% for cohort 2; 12-year rates for developing an invasive IBE were 7.5% in cohort 1 and 13.4% in cohort 2. Study cohort and tumor size were significantly associated with risk for IBE.
Women with ductal carcinoma in situ who undergo surgical resection without radiation have an increased risk of developing recurrence.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|